Access Pharmaceuticals closes acquisition of MacroChem Corp.

Access Pharmaceuticals Inc has closed the acquisition of MacroChem Corp through the issuance of 2.5 M shares of Access Pharmaceuticals' common stock, as previously announced. Access Pharmaceuticals gains the rights to MacroChem's product portfolio which includes two clinical stage oncology products, 4-thio Ara-C (Thiarabine), which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium phenylbutyrate, which is licensed from the NIH. MacroChem's portfolio of late stage clinical drug candidates includes Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection that has already completed two Phase III clinical …